

**International Patient Advocacy Group Meeting**

**2023**

# **ANNUAL SMA CONFERENCE**

**Challenges in Standard of Care and Access Wins**  
**Alpana Sharma / Moumita Ghosh**




# Cure SMA Foundation of India

## Who we are

CureSMA India is a parent led Non Profit Registered Organization since 2014.

We represent around 1100+ registered patients, mostly children battling the life-threatening neuromuscular genetic disorder Spinal Muscular Atrophy.

## We represent ALL SMA Types



## Prevalence & Incidence of SMA in India.

Current live births in India 67385

(source UNICEF India, <https://www.unicef.org/india/key-data>),

1 SMA child is born every 2 to 2.5 hours in India

11 SMA children are born every day in India

4015 SMA children are born every year in India


## VISION & MISSION

We dream of an SMA free world and a barrier free universal healthcare for all.

We believe in working to co-create solutions



# CureSMA India - Our Geographic Coverage, Patient Population



**Approx. 1100+ registered patients  
(and increasing.....)**

SMA Type 1	SMA Type 2	SMA Type 3	SMA Type 4
10%	63%	25%	2%

(Note: Indicative break-down only)

- ☞ Patient registry and on-boarding increasing (diagnosis and discovery +awareness)
- ☞ Formalised on-boarding process of CureSMA India

- 🕒 Critical patients in network
- 🕒 48 + lives lost ( in the last 6 months)



CureSMA City Co-ordinators

# Cure SMA India's Journey so far - POLICY MAKING AND ENGAGEMENT WITH GOVERNMENT OF INDIA

- POLICY MAKING AND ENGAGEMENT WITH- DCGI-MoHFW,
- New Rules for Clinical Trials
- Draft Rules for Compassionate Use Program



Virtual Round Table Discussion On  
"UNIVERSAL ACCESS TO LIFE SAVING  
MEDICINES - CHALLENGES & SOLUTIONS"

This is first multistakeholder Discussion on Spinal Muscular Atrophy in India. This is starting point of identifying , categorizing challenges and working towards finding a sustainable universal access to life saving medicines.  
9th AUGUST 6 PM TO 8.30 PM

**Dr. V G Somani**  
DCGI, CDSCO  
(Chief Guest)

**Dr. A K Pradhan**  
Dy. DCGI, CDSCO

**Ms. Nicole Gusset**  
VC, SMA Europe

**Prof. (Dr.) Sheffali Gulati**  
Paediatric Neurologist, AIIMS

**Prof. Marcin Czech**  
HOD Pharmacoeconomics  
Inst. of Mother and Child, Poland

**Dr. Renu Suthar**  
Paediatric Neurologist  
PGIMER, Chandigarh

**Mr. Kacper Rucinski**  
Board Member  
SMA Europe

**Dr. Sanjukta Dey**  
Paediatric Pulmonologist  
Peerless Hospital, Kolkata

**Dr. Subir Roy**  
County Medical Lead  
(Orphan Diseases) Takeda

**Dr. Ratna Dua Puri**  
Prof. & Chairperson,  
Institute of Medical Genetics  
& Genomics, SGRH

**Ms. Archana Panda**  
Director CuresmaIndia

**Dr. Kausik Mandal**  
Additional Prof., Medical Genetics,  
SGPGIMS, Lucknow

**Ms. Alpana Sharma**  
Director CuresmaIndia

**Dr. Subhrojyoti Bhowmick**  
Director Academic Clinical  
Research,  
Peerless Hospital Kolkata  
(Moderator)

**Dr. Neelu Desai,**  
MD DNB Pediatric Neurologist  
PD Hinduja Hospital & MRC

**Ms. Moumita Ghosh**  
Director CuresmaIndia

**Dr. Smilu Mohanlal**  
Paediatric Neurologist  
ASTER MIMS, Calicut

**Ms. Binota Roy**  
Advocate

**Mr. Sameer Savkur**  
Senior Director  
Biogen Indec Boston

**Dr. Anupam Kulkarni**  
Rare Disease Partner  
Roche India

**Mr. JT Tibung**  
Medical Director  
Biogen APAC, Hong Kong

**Ms. Vaishali Iyer**  
Head-Communication &  
Patient Advocacy, Novartis, India

**Dr. Samir Sangitrao**  
Assoc Director Regulatory Affairs  
Roche India

[Part II-Section 3(i)] भारत का राजपत्र : असाधारण 147

MINISTRY OF HEALTH AND FAMILY WELFARE  
(Department of Health and Family Welfare)

NOTIFICATION  
New Delhi, the 19th March, 2019

**G.S.R.227(E)** .— WHEREAS the draft of the New Drugs and Clinical Trials Rules, 2018 was published, in exercise of the powers conferred by sub-section (1) of section 12 and sub-section (1) of section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), in the Gazette of India, Extraordinary, Part II, section 3, sub-section (i) vide notification number G.S.R. 104(E), dated the 1<sup>st</sup> February, 2018, by the Central Government, after consultation with the Drugs Technical Advisory Board, inviting objections and suggestions from all persons likely to be affected thereby, before the expiry of a period of forty-five days from the date on which copies of the Official Gazette containing the said notification were made available to the public;

AND WHEREAS, copies of the Official Gazette containing the said notification were made available to the public on the 7<sup>th</sup> February, 2018;

AND WHEREAS, all objections and suggestions received in response to the said draft notification have been duly considered by the Central Government;

AND WHEREAS, the Hon'ble Supreme Court of India in Writ Petition(s) (Civil) No (s). 33/2012 Swathaya Adhikar Manch, Indore and another Versus Union of India and others with W.P.(C) No. 79/2012 (PIL-W), *inter alia*, observed that new clinical trial rules shall be finalised urgently;

NOW, THEREFORE, in exercise of the powers conferred by section 12 and section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government, after consultation with the Drugs Technical Advisory Board, hereby makes the following rules, namely:—

12 THE GAZETTE OF INDIA : EXTRAORDINARY [Part II—Sec. 3(i)]

MINISTRY OF HEALTH AND FAMILY WELFARE  
(Department of Health and Family Welfare)

NOTIFICATION  
New Delhi, the 5<sup>th</sup> June, 2020

**G.S.R. 354(E)**—The following draft of certain rules to amend the New Drugs and Clinical Trials Rules, 2019 which the Central Government proposes to make, in exercise of the powers conferred by sub-section (1) of section 12 and sub-section (1) of section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940) and in consultation with the Drugs Technical Advisory Board is hereby published for information of all persons likely to be affected thereby and notice is hereby given that the said draft rules shall be taken into consideration on or after the expiry of a period of fifteen days from the date on which the copies of the Gazette of India containing these draft rules are made available to public;

Objections and suggestions which may be received from any person within the period specified above will be considered by the Central Government;

Objections and suggestions, if any, may be addressed to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, Room No. 414 A, D Wing, Nirman Bhawan, New Delhi - 110011 or emailed at [drugsdtr-mohfw@gov.in](mailto:drugsdtr-mohfw@gov.in).

DRAFT RULES

- (1) These rules may be called the New Drugs and Clinical Trials (.....Amendment) Rules, 2020.
- (2) They shall come into force on the date of their final publication in the Official Gazette.

2. In the New Drugs and Clinical Trials Rules, 2019.



Virtual Round Table Discussion On  
"UNIVERSAL ACCESS TO LIFE SAVING  
MEDICINES - CHALLENGES & SOLUTIONS"

This is first multistakeholder Discussion on Spinal Muscular Atrophy in India. This is starting point of identifying , categorizing challenges and working towards finding a sustainable universal access to life saving medicines.  
9th AUGUST 6 PM TO 8.30 PM

**Dr. V G Somani**  
DCGI, CDSCO  
(Chief Guest)

**Dr. A K Pradhan**  
Dy. DCGI, CDSCO

**Ms. Nicole Gusset**  
VC, SMA Europe

**Prof. (Dr.) Sheffali Gulati**  
Paediatric Neurologist, AIIMS

**Prof. Marcin Czech**  
HOD Pharmacoeconomics  
Inst. of Mother and Child, Poland

**Dr. Renu Suthar**  
Paediatric Neurologist  
PGIMER, Chandigarh

**Mr. Kacper Rucinski**  
Board Member  
SMA Europe

**Dr. Sanjukta Dey**  
Paediatric Pulmonologist  
Peerless Hospital, Kolkata

**Dr. Subir Roy**  
County Medical Lead  
(Orphan Diseases) Takeda

**Dr. Ratna Dua Puri**  
Prof. & Chairperson,  
Institute of Medical Genetics  
& Genomics, SGRH

**Ms. Archana Panda**  
Director CuresmaIndia

**Dr. Kausik Mandal**  
Additional Prof., Medical Genetics,  
SGPGIMS, Lucknow

**Ms. Alpana Sharma**  
Director CuresmaIndia

**Dr. Subhrojyoti Bhowmick**  
Director Academic Clinical  
Research,  
Peerless Hospital Kolkata  
(Moderator)

**Dr. Neelu Desai,**  
MD DNB Pediatric Neurologist  
PD Hinduja Hospital & MRC

**Ms. Moumita Ghosh**  
Director CuresmaIndia

**Dr. Smilu Mohanlal**  
Paediatric Neurologist  
ASTER MIMS, Calicut

**Ms. Binota Roy**  
Advocate

**Mr. Sameer Savkur**  
Senior Director  
Biogen Indec Boston

**Dr. Anupam Kulkarni**  
Rare Disease Partner  
Roche India

**Mr. JT Tibung**  
Medical Director  
Biogen APAC, Hong Kong

**Ms. Vaishali Iyer**  
Head-Communication &  
Patient Advocacy, Novartis, India

**Dr. Samir Sangitrao**  
Assoc Director Regulatory Affairs  
Roche India


# Cure SMA India- Seeking multi stakeholder support in creating pathway for Sustainable healthcare ecosystem for SMA

## Short term goal

- Management of disease SMA with standard protocols and best practices
- Access to available treatment immediately at affordable rates

## Long term goal

- Life long continued access to affordable treatment
  - CORPORATE FUNDS & GOVT FUNDS
- Care & Management with standard protocols at nearest convenient center.
- Social inclusion, accessibility, education and employment, empowerment & livelihood.
- Genetic screening, new born screening
- Pathway towards early access to life saving medicines to save lives and preserve functionality as much as possible & create a sustainable ecosystem for SMA patients.



# RISDIPLAM LAUNCH

22:12 59%

Risdiplam launch...

## INVITATION

**PUSHING THE BOUNDARIES**  
in Treatment of SMA



10<sup>th</sup> July, 2021

5:00 PM TO 9:00 PM


Registration and Meeting Link

<https://roche.virtualvenue3d.com/>




Cure SMA India  
Hope Beyond Boundaries

6:07 bigmarker.com/conferences/9





Chat

8:57 bigmarker.com/conferences/9



Chat

9:03 bigmarker.com/conferences/9906769146ce/bigroom



Chat



New Delhi, the 30<sup>th</sup> September, 2021

G.S.R. ... (E) - In exercise of the powers conferred by sub-section (1) of section 28 of the Customs Act, 1962 (52 of 1962) and sub-section (12) of section 3 of Customs Tariff Act, 1975 (51 of 1975), the Central Government, on being satisfied that it is necessary in the public interest so to do, hereby makes the following further amendments in the notification of the Government of India, in the Ministry of Finance (Department of Revenue), No. 90/2017-Customs, dated the 30th June, 2017, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (2), vide number G.S.R. 785(E), dated the 30<sup>th</sup> June, 2017, namely:-

In the said notification, -

(a) in the TABLE, for S. No. 607 and the entries relating thereto, the following S. No. and entries shall be substituted, namely:-

(1)	(2)	(3)	(4)	(5)	(6)
607.	9804	The following goods, imported for personal use, namely:- (a) the life saving drugs or medicines (including diagnostic test kits) specified in List 4; (b) other life saving drugs or medicines; (c) life saving medicines for treatment of Spinal Muscular Atrophy or Duchenne Muscular Dystrophy, namely:- (i) Zolgensma (Zinc Finger Nucleotidyltransferase) (ii) Vilepro (Vilodareson) (iii) any other medicine for treatment of the said diseases.	Nil	Nil	16%

(b) In the Annexure, -

(i) For Condition No. 16, the following condition shall be substituted, namely:-

16.	If, -
	(a) the goods are imported by an individual for personal use;
	(b) it is certified in the Form as applicable and specified below, by the Director General or Deputy

Director General or Assistant Director General, Health Services, New Delhi, Director of Health Services of the State Government or the District Medical Officer/Civil Surgeon of the district, in each individual case.

(1) Form for medicines used for treatment of Spinal Muscular Atrophy / Duchenne Muscular Atrophy covered under sub-section (1) of clause (c) of S. No. 607 of the Table:-  
 Certificate No. .... of ..... (Year) .....  
 Certified that the medicine ..... (name of the medicine) to be used for the treatment of ..... (patient name), is a life saving medicine used specifically for Spinal Muscular Atrophy / Duchenne Muscular Atrophy and exemption from the payment of customs duty and Integrated GST is recommended.

Signature with date of Director General / Deputy Director General / Assistant Director General, Health Services, New Delhi or Director of Health Services or District Medical Officer/Civil Surgeon.

or

(2) Form for life saving drugs or medicines, not covered under (1) above, being imported under clause (b) of S. No. 607 of the Table:-  
 Certificate No. .... of ..... (Year) .....  
 Certified that the drug / medicine ..... (name of the drug / medicine) to be used for the treatment of ..... (disease name) and exemption from the payment of customs duty is recommended.

Signature with date of Director General / Deputy Director General / Assistant Director General, Health Services, New Delhi or Director of Health Services or District Medical Officer/Civil Surgeon.

and  
 (c) the importer produces the said certificate to the Deputy Commissioner of Customs or the Assistant Commissioner of Customs, as the case may be, at the time of clearance or given an undertaking to accept that the Deputy Commissioner or the Assistant Commissioner in furnish the said certificate within such period as may be specified by the Deputy Commissioner or the Assistant Commissioner, failing which to pay duty leviable thereon.



**Vivek Tankha** ✓  
 @VTankha

इन बच्चों को @PMOIndia के साथ पूरे देश की सहानुभूति और मदद की ज़रूरत है। मैंने इस इशू संसद में उठाया था। @nsitharaman ने मुझे assure किया था की इन बच्चों के लिए वो पूरा प्रयास करेगी। इस समस्या को सुलझाने का वक्त आ चुका है। @OfficeOf\_MM को भी सक्रिय होना पड़ेगा। 🙏🙏

Translate Tweet

**Subhash Kumar** @Subhash44... · 05/10/21

Replying to @VTankha and @priyankagandhi

आदरणीय,  
 श्री@VTankhaजी 🙏  
 हमारी आवाज संसद में उठाएँ और आदरणीय श्री नरेंद्र मोदी जी को अवगत कराएं  
 कृपया #SMA बच्चों को बचाएं हम बच्चों को खो रहे हैं दवाई #Evrysi (risdiplam)  
 इसे हम खरीद नहीं सकते हम पर दया करें



## 'Institutionalise import exemptions for SMA kids'

Baby Teera, who suffers from a rare genetic disease, has got an exemption of customs duty and GST waiver worth over ₹5 crore on the import of Zolgensma — a gene therapy medication for SMA

**Teera's parents and family** have requested the central government to institutionalise these exemptions on the larger basket of other life-saving drugs from the west.

The 18-month-old baby Teera, who suffers from SMA Type 1, has been treated with Zolgensma, a life-saving drug worth ₹5 crore. The drug is imported from the USA. The parents have requested the central government to institutionalise these exemptions on the larger basket of other life-saving drugs from the west.

The 18-month-old baby Teera, who suffers from SMA Type 1, has been treated with Zolgensma, a life-saving drug worth ₹5 crore. The drug is imported from the USA. The parents have requested the central government to institutionalise these exemptions on the larger basket of other life-saving drugs from the west.

The 18-month-old baby Teera, who suffers from SMA Type 1, has been treated with Zolgensma, a life-saving drug worth ₹5 crore. The drug is imported from the USA. The parents have requested the central government to institutionalise these exemptions on the larger basket of other life-saving drugs from the west.

- We have been constantly meeting and advocating with both State and Central Government regarding treatment access and creating robust infrastructure for SMA Patients and families. This has resulted in Custom and Import Duty Exemptions for one of the SMA Drug



# Access Win – Kerala NHM & RACE



Kerala govt. is proving Risdiplam for young SMA patients. The initial procurement is expected to be continued & the govt. may extend the programme to more patients. This is Outcome of the hard work by all of us (CureSMA India especially Dr Razeena, Roche and State NHM)



**KERALA LENDS HELPING HAND TO CHILDREN IDENTIFIED WITH SPINAL MUSCULAR ATROPHY (SMA)**

Government of Kerala is initiating proactive steps to diagnose, treat and manage children identified with Spinal Muscular Atrophy. Parents of children affected by SMA are requested to apply for treatment assistance in the prescribed format given in the website of Arogyakeralam ([arogyakeralam.gov.in](http://arogyakeralam.gov.in)) and Dept. of Health Services ([dhs.kerala.gov.in](http://dhs.kerala.gov.in)).

172 applications have been received by Govt. seeking treatment assistance so far. Treatment expense will range from 24 lakhs to 72 lakhs per child. In order to facilitate expert medical treatment to said children and support this noble initiative, donations are solicited from generous and broad-minded people across the country.

**DOINATIONS CAN BE SENT TO**

**STATE BANK OF INDIA**  
Thiruvananthapuram, City-700026  
Account No. 39229924884  
IFSC Code: SBIN0070028

For more information contact DISHA helpline: 1056, 104 (toll free) / 0471 2552056

GOVERNMENT OF KERALA  
DEPARTMENT OF HEALTH AND FAMILY WELFARE

**R – Railways**  
**A- Army & Navy**  
**C – Central govt employees**  
**E - ESI**



# Strategic Global Partnership

## Announcing Strategic Partnership



**TOGETHER**

**WE WILL MAKE A CHANGE**

CureSMA India and CureSMA USA announce partnership to build a long-lasting ecosystem for SMA patients in India

## Cure SMA India & SMA Europe Strategic Partnership



**TOGETHER**


**WE WILL MAKE A CHANGE**

Cure SMA India and SMA Europe announce partnership to build a long-lasting ecosystem for SMA patients in India

# Standard of Care (SoC)

Treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by healthcare professionals


Standards are created or reviewed by experts in the relevant field. They include researchers, care providers, patients and families, who form a technical committee.



The Standard of Care is the benchmark that determines whether professional obligations to patients have been met.

In a rare disease like SMA, following a SoC is important to provide the best palliative and medical care available.

# Standard of Care Review & Development Process (Health Standard Organisations Model)



# Standard of Care (SoC): Challenges, Solution & Benefits



## CHALLENGES

- Low awareness about the condition
- Poor clinical skills due to low disease prevalence
- Focus on symptomatic care rather on holistic management
- Focus on prognosis rather on Quality of Life
- Lack of resources, infrastructure and skilled manpower
- Financial constraints



## SOLUTIONS

- Awareness activities
- Patient registry
- Education programs to enhance knowledge & skills
- Including Rare Disease in medical curriculum more elaborately
- Advocating importance of holistic care and multidisciplinary management for better quality of life with different stakeholders
- Policy level advocacy to include Rare Disease management and treatment in Government Healthcare program and health insurances





## BENEFITS

- Multidisciplinary SMA clinics provide regular and comprehensive care
- Standardization of care protocol lowers cost and improve outcome
- Established centres and experienced clinicians to initiate Disease modifying therapy and clinical trials, studies and research

# Standard of Care: Evolving Indian Scenario

2012 → 2017 → 2023



# Multidisciplinary SMA Clinics in India

- CureSMA India started its first Multidisciplinary SMA Clinic in 2017 in collaboration with Peerless Hospital, Kolkata (Eastern India).
- Presently, in collaboration with various private/government hospitals, **seven** Multidisciplinary SMA Clinics are running across India in different geographical locations.
- Multidisciplinary Clinics and present SMA ecosystem in India is catering SMA individuals of India (including more than 1500 registered members of CureSMA India) and neighbouring countries like Bangladesh, Nepal, Bhutan, Sri Lanka and Pakistan (SAARC – South Asian Association for Regional Cooperation – countries).



# CureSMA India SMA Task Force Team

- CureSMA India invited 21 renowned clinicians from various tertiary care hospitals across India to form the first SMA Task Force Team of India in 2020.
- The first SMA Task Force Team drafted COVID-19 guidelines for Indian SMA patients (available in CureSMA India website).
- The present CureSMA India Task Force includes 39 clinicians.
- This team is currently working on drafting Type-specific SMA guidelines for HCPs and caregivers.

## ALL INDIA SMA TASK FORCE TEAM



**Prof. (Dr.) Madhulika Kabra**  
Neurologist,  
AIIMS, New Delhi



**Prof. (Dr.) Sheffali Gulati**  
Paediatric Neurologist, Director, Prof. Paediatrics, Moulana Azad  
AIIMS, New Delhi



**Dr. Seema Kapoor**  
Medical College & Hospital, Delhi



**Dr. Renu Suthar**  
Paediatric Neurologist  
PGIMER, Chandigarh



**Dr. Mamta Muranjan**  
Clinical Geneticist,  
KEM Hospital, Mumbai



**Dr. Siddhart Shah**  
Paediatric Neurologist,  
RICN, Gujarat



**Dr. Saumyajit Basu**  
Spine Surgeon,  
Kothari Medical Centre, Kolkata



**Dr. Sanjukta Dey**  
Paediatric Pulmonologist  
Peerless Hospital, Kolkata



**Dr. Subhrojyoti Bhowmick**  
Director Academic  
Clinical Research,  
Peerless Hospital, Kolkata



**Dr. Ankit Parakh**  
Paediatric Pulmonologist,  
BLKSS Hospital, Delhi



**Dr. Alpana Kondekar**  
Associate Prof. Paediatrics,  
Nair Hospital, Mumbai



**Prof. Ratna Dua Puri**  
Medical Genetics,  
SGRH, New Delhi



**Dr. Vishnu VY**  
Neurologist,  
AIIMS, Delhi



**Dr. Mary Iype**  
Paediatric Neurologist,  
Trivandram Medical College,  
Kerala



**Dr. Vyunkta Raju**  
Paediatric Neurologist,  
Indira Gandhi Institute of Child Health,  
Bengaluru



**Dr. Avi Shah**  
Paediatric Orthopedic,  
SRCC Hospital, Mumbai



**Dr. Vinitha Vijayaraghavan**  
Paediatrics  
Gastroenterologist,  
Aster MIMS, Calicut



**Dr. Pramod K Sunderaswar**  
Spine Surgeon,  
Aster MIMS, Calicut



**Dr. C. P. Ravi**  
Paediatric Neurologist  
Aster, Bengaluru



**Dr. Debasis Panigrahi**  
Paediatric Neurologist,  
Jaggarnath Hospital, Odisha



**Prof. Dr. Usha Rani**  
Paediatrician,  
HoD, Nilofeur Hospital,  
Hyderabad




**Dr. Ashok Gupta**  
Paediatrics,  
JK Lone Hospital, Jaipur



**Dr. Ashok Jahuri**  
Paediatric Orthopedic &  
Spine Surgeon, Max Super  
Speciality Hospital, Mumbai



**Dr. Anaita Hegde**  
Paediatric Neurologist,  
SRCC Hospital, Mumbai



**Dr. Kausik Mandal**  
Additional Prof., Medical Genetics,  
SGPGIMS, Lucknow



**Dr. Shruti Parab**  
Physiotherapist,  
MGM Hospital, Mumbai




**Ms. S. Maitra Nag**  
Nutritionist,  
Peerless Hospital, Kolkata



**Dr. Mona Patel**  
Paediatric Physiotherapist,  
Arsh Paediatric Rehabilitation Clinic,  
Ahmedabad



**Dr. Nilofar Vora**  
Physiotherapist,  
Arsh Physiotherapy Clinic,  
Ahmedabad



**Dr. Shantanu Kumar Dey**  
Senior Physiotherapist,  
Narayan Multispecialty, Kolkata



**Dr. Priyanshu Mathur**  
Paediatrician &  
Rare Disease Specialist,  
JK Lone Hospital, Jaipur



**Dr. Jasodhara Chaudhuri**  
Paediatric Neurologist,  
IPGIMER, Kolkata



**Dr. Ashis Das**  
Adult Neurologist,  
Peerless Hospital, Kolkata



**Dr. Sandeep Patil**  
Paediatric Neurologist, Deenanth  
Mangeshkar Hospital, Pune



**Dr. Arijit Chatterjee**  
Paediatric Neurologist,  
Peerless Hospital, Kolkata



**Dr. R. M. Sundar**  
Physiotherapist,  
Bengaluru



**Dr. Puja Marathe**  
Nutritionist,  
Rainbow Children Hospital, Hyderabad



**Dr. Sarvanan Sundarakrishnan**  
CPO



**Dr. Pankaj Sinha**  
CPO



*We sincerely **'Thank You'** for your time and consideration.*

*Our families are truly looking up to you, for your support in our journey to  
'Change & Save lives'!*

**Cure SMA Foundation of India**

501/D23, Ireo Victory Valley, Sector 67, Gurugram, Haryana, India – 122018

 @CureSMAIndia  [curesmaindia.org](mailto:info@curesmaindia.org)  [info@curesmaindia.org](mailto:info@curesmaindia.org)